MedTrace Logo

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT00892736 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2018-06-29

No results posted yet for this study

Summary

This phase I trial studies the side effects and best dose of veliparib in treating patients with malignant solid tumors that do not respond to previous therapy. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • Basal-Like Breast Carcinoma
  • BRCA1 Mutation Carrier
  • BRCA2 Mutation Carrier
  • Breast Carcinoma
  • Estrogen Receptor Negative
  • HER2/Neu Negative
  • Hereditary Breast and Ovarian Cancer Syndrome
  • Ovarian Carcinoma
  • Pancreatic Carcinoma
  • Progesterone Receptor Negative
  • Prostate Carcinoma
  • Recurrent Breast Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Primary Peritoneal Carcinoma
  • Solid Neoplasm
  • Triple-Negative Breast Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Veliparib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Shannon Puhalla · University of Pittsburgh Cancer Institute (UPCI)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-20
Primary Completion
2017-05-19
Completion
2017-05-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892736 on ClinicalTrials.gov